Delivery Order SPE2DB20D1100-SPE2DB25FD4A1
- Not listed
- The Defense Logistics Agency awarded a $18,136.65 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of August 22, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $106,878.66 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen injectors. The contract employs firm fixed pricing and carries an ultimate completion date of September 29, 2025. This non-set-aside award was competitively placed and will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $40,155.43 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside transaction executed on September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with extensive experience...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at approximately $121,000 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen injectors. The contract, issued on September 22, 2025, with completion targeted for September 23, 2025, represents a firm fixed-price transaction with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 comprehensive...
- The Defense Logistics Agency awarded a $38,306.42 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of August 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations for federal...
- The Defense Logistics Agency awarded a delivery order valued at approximately $77.4K to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injections, with a completion deadline of September 30, 2025. This non-set-aside competitive award reflects AmerisourceBergen's established role as a critical pharmaceutical distributor supporting federal medical procurement requirements. The delivery order will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania, utilizing...
- The Defense Logistics Agency awarded a $59,150 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of August 28, 2025. This non-set-aside competitive award was issued on August 27, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. As a child delivery order under a larger indefinite delivery contract vehicle, this award represents a tactical pharmaceutical...
- The Defense Logistics Agency awarded a $127,949.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen injectors, with a completion date of September 19, 2025. This competitively awarded, non-set-aside contract represents a child delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,588.83 for SKYRIZI 150 mg/mL pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price contract, which received no set-aside designation, represents a competitive award to the major pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD4A1Delivery Order
The Defense Logistics Agency awarded a $28,786.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors, with an ultimate completion date of July 15, 2025. This non-set-aside delivery order represents a competitive award to the pharmaceutical distributor, which is headquartered in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement extending through December 2026 that enables the company to supply comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly for Defense Health Agency and military healthcare systems. The company's federal contract portfolio demonstrates extensive capability in delivering brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. This delivery order for SKYRIZI, a dermatological treatment, exemplifies the company's role as a primary pharmaceutical supplier within the DLA's medical supply chain and reflects its competitive positioning among federal healthcare contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.8k | 7/14/25 |